About Cartalax
Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells
Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.
Cartalax Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
1 source cited · 1 moderate
1 In vitro
KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging
Advances in Gerontology · 2023
Research in human mesenchymal stem cells found that the KE peptide (Lys-Glu) increased SIRT1 gene expression and protein synthesis 6- to 8.2-fold in young MSCs while reducing PARP1 and PARP2 expression 2- to 5-fold during aging, with molecular modeling confirming direct DNA binding interactions; provides mechanistic context for the geroprotective effects of related cartilage tissue-derived peptides including cartalax.
Cartalax Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Cartalax — Providers & Availability
4 providersStay updated on verified Cartalax providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Cartalax
Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging.
cartilage regeneration, joint repair, chondrocyte function support.
Research on Cartalax primarily documents effects related to cartilage regeneration and joint repair and chondrocyte function support. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Cartalax include none established. This is educational information only — consult a qualified healthcare professional before use.
4 providers in the directory currently offer Cartalax.
Research in human mesenchymal stem cells found that the KE peptide (Lys-Glu) increased SIRT1 gene expression and protein synthesis 6- to 8.2-fold in young MSCs while reducing PARP1 and PARP2 expression 2- to 5-fold during aging, with molecular modeling confirming direct DNA binding interactions; provides mechanistic context for the geroprotective effects of related cartilage tissue-derived peptides including cartalax.